Rezūm Therapy in Very Elderly Men With BPH: Two-Year Outcomes From a Multicenter Cohort

Area of Science:

• Urology
• Minimally Invasive Surgery
• Geriatric Medicine

Background:

• Rezūm water vapor thermal therapy is an established minimally invasive treatment for benign prostatic hyperplasia (BPH).
• Limited real-world data exists on the 2-year outcomes of Rezūm therapy in men aged 80 years and older.

Purpose of the Study:

• To evaluate the 2-year safety and efficacy of Rezūm water vapor thermal therapy in men aged 80 years and older with BPH.
• To assess changes in International Prostate Symptom Score (IPSS), IPSS Quality of Life (QoL) subscore, peak urinary flow rate (Qmax), and post-void residual volume (PVR).

Main Methods:

• A prospective registry study was conducted within the International Rezūm Registry database.
• Data from 58 men aged ≥80 years who underwent Rezūm therapy were analyzed.
• Patients were assessed at baseline and at 3, 6, 12, and 24 months for symptom scores, urinary flow rates, and residual volumes.

Main Results:

• Significant improvements were observed in mean IPSS (19.8 to 12.4) and IPSS QoL scores (4.2 to 2.6) at 24 months.
• Mean Qmax increased from 8.5 to 15.0 mL/s, and mean PVR decreased from 115.5 to 42.8 mL over 24 months.
• Adverse events were infrequent, including urinary tract infections (8.6%), epididymitis (5.2%), and acute urinary retention (3.4%), with only one hospitalization.

Conclusions:

• Rezūm water vapor thermal therapy is a safe and effective treatment option for BPH in elderly men (≥80 years).
• The therapy demonstrates durable improvements in lower urinary tract symptoms and functional outcomes.
• The procedure is associated with a low incidence of adverse events in this specific patient population.